Table 4. Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available.
| Characteristic | CCAE (age 0–13) | CCAE (age 14–39) | CCAE (age 40–64) | Medicaid (age 0–13) | Medicaid (age 14–39) | Medicaid (age 40–64) | Medicare (age > = 65) |
|---|---|---|---|---|---|---|---|
| n | 9 893 962 | 22 824 848 | 26 561 525 | 4 151 506 | 3 032 191 | 1 130 797 | 5 429 266 |
| Female | 48.1% | 57.5% | 54.8% | 48.4% | 69.3% | 60.8% | 55.2% |
| Age (median, mean) | 6, 6.01 | 27, 26.3 | 51, 51.23 | 5, 5.14 | 21, 22.5 | 50, 50.57 | 72, 73.82 |
| Fraction of patients with incident use of a given minimum number of distinct PGx drugs within the observed four-year time window. First value for pre-emptive scenario, second value in brackets for 'reactive pre-emptive' scenario. | |||||||
| > = 1 drugs | 11.2% (100.0%) | 30.4% (100.0%) | 42.2% (100.0%) | 14.0% (100.0%) | 40.2% (100.0%) | 55.5% (100.0%) | 50.6% (100.0%) |
| > = 2 drugs | 1.1% (9.9%) | 9.1% (30.0%) | 17.8% (42.2%) | 1.8% (12.1%) | 15.3% (38.1%) | 32.8% (59.0%) | 27.5% (54.4%) |
| > = 3 drugs | 0.2% (2.1%) | 3.1% (10.2%) | 7.5% (17.8%) | 0.5% (3.3%) | 6.5% (16.1%) | 18.5% (33.1%) | 13.8% (27.3%) |
| > = 4 drugs | 0.1% (0.5%) | 1.1% (3.8%) | 3.1% (7.4%) | 0.1% (0.9%) | 2.9% (7.2%) | 9.9% (17.8%) | 6.4% (12.7%) |
| > = 5 drugs | 0.0% (0.%) | 0.4% (1.4%) | 1.3% (3.0%) | 0.0% (0.3%) | 1.3% (3.2%) | 5.0% (9.1%) | 2.8% (5.5%) |
| > = 6 drugs | 0.0% (0.0%) | 0.2% (0.6%) | 0.5% (1.2%) | 0.0% (0.1%) | 0.6% (1.5%) | 2.4% (4.3%) | 1.1% (2.3%) |
| PGx drugs with most frequent incident use within four-year time window | |||||||
| Rank 1 | Codeine (7.2%) | Codeine (9.4%) | Codeine (9.5%) | Codeine (8.8%) | Oxycodone (15.0%) | Oxycodone (15.8%) | Simvastatin (13.4%) |
| Rank 2 | Lansoprazole (1.7%) | Oxycodone (7.8%) | Oxycodone (8.8%) | Lansoprazole (1.4%) | Codeine (10.6%) | Tramadol (13.8%) | Metoprolol (10.8%) |
| Rank 3 | Omeprazole (0.6%) | Tramadol (4.0%) | Simvastatin (8.2%) | Risperidone (1.1%) | Tramadol (8.3%) | Omeprazole (10.9%) | Omeprazole (9.2%) |
| Rank 4 | Atomoxetine (0.5%) | Sertraline (3.2%) | Omeprazole (6.2%) | Omeprazole (1.0%) | Citalopram (4.8%) | Simvastatin (9.6%) | Tramadol (8.5%) |
| Rank 5 | Sertraline (0.5%) | Omeprazole (3.1%) | Tramadol (6.2%) | Oxycodone (0.7%) | Omeprazole (4.6%) | Citalopram (7.6%) | Codeine (8.2%) |
| Rank 6 | Risperidone (0.4%) | Citalopram (2.9%) | Metoprolol (4.4%) | Atomoxetine (0.6%) | Sertraline (4.3%) | Metoprolol (7.3%) | Oxycodone (8.0%) |
| Rank 7 | Oxycodone (0.3%) | Escitalopram (2.2%) | Citalopram (3.3%) | Sertraline (0.6%) | Aripiprazole (1.9%) | Codeine (7.1%) | Warfarin (5.6%) |
| Rank 8 | Aripiprazole (0.2%) | Pantoprazole (1.3%) | Sertraline (2.8%) | Aripiprazole (0.5%) | Risperidone (1.8%) | Sertraline (4.4%) | Clopidogrel (5.1%) |
CCAE: Truven MarketScan® Commercial Claims and Encounters dataset. PGx drugs: drugs for which pharmacogenomic guidelines are available.